A Prospective, Randomized Clinical Trial of Cryotherapy Vs

Slides:

Advertisements

Similar presentations

A Phase Ib Clinical Trial of PV701, a Milk-Derived Protein Extract, for the Prevention and Treatment of Oral Mucositis in Patients Undergoing High-Dose.

Advertisements

Identification of CD137+ IFN-g- CD4+ Alloreactive T Cells Post Myeloablative Double Cord Blood Transplant: A Synergistic Role in the Graft Verus Graft.

Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review

Stephanie J. Lee, Loretta A. Williams

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

A Phase 1/2 Trial of Carfilzomib + High Dose Melphalan Conditioning for Auto-HCT Followed by Carfilzomib Maintenance for Patients with Relapsed Multiple.

Muzaffar H. Qazilbash, MD, Peter Thall, PhD, Patricia S

How to Treat MDS without Stem Cell Transplantation

Temporal Changes in Plerixafor Administration and Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial in Multiple Myeloma

Using A3 Methodology to Identify the Root Cause of a Chemotherapy Error in a Hematopoietic Stem Cell Transplant Patient Kathlene DeGregory, PharmD, BCOP,

Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Is Associated with Reduced Hospital Days and Utilization of Opiate Infusion and Total Parenteral.

A Response Adapted Approach to Induction Treatment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Gunjan L. Shah,

Continuous Intravenous Immunoglobulin and Platelet Infusion in Allogeneic Stem Cell Transplant Patients with Allo-Immune Thrombocytopenia Katerina Ancevski,

Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma Brian Hess, MD, Kathryn Trinkaus, Ph.D.,

Impact of Pre-Transplant Minimal Residual Disease in Patients with AML Undergoing Myeloablative Cord Blood Transplantation Filippo Milano, MD, PhD, Brent.

Inhaled Cyclosporine Solution for the Treatment of Bronchiolitis Obliterans Following Hematopoietic Stem Cell Transplantation (HSCT) or Lung Transplantation

Higher Apheresis Blood Volumes Are Associated with a Reduction in Relapse Risk and Improved Survival in Patients Undergoing Reduced Intensity Allogeneic.

Gain of Chromosome 1q Portends Worse Prognosis in Multiple Myeloma Patients Treated with Novel Agent Based Induction Regimens Even after Autologous Transplantation

Access to Hematopoietic Cell Transplantation in the United States

Alemtuzumab/Low Dose Radiation Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Sickle Cell Disease.

Eltrombopag Eliminates Transfusion Requirements in a Patient with Fanconi Anemia Ashish Gupta, MD, MPH, Rasmi Palassery, MD, Sanjay Ahuja, MD, MBA, Rachel.

Case Report: 52 Year-Old Male 11 Months after MUD for Angionimmunoblastic T Cell Lymphoma Developed Acute Fibrinous Organizing Pneumonitis Successfully.

A Phase Ib Clinical Trial of PV701, a Milk-Derived Protein Extract, for the Prevention and Treatment of Oral Mucositis in Patients Undergoing High-Dose.

Jane Kempenich, Kelly Buck, John Hermanson, Jason Dehn, MPH

Stephanie J. Lee, Loretta A. Williams

Treatment of Severe Mucositis Pain with Oral Ketamine Mouthwash

Smartphrases: Streamlining Electronic Documentation of Patient Data for CIBMTR Reporting and Clinical Research Compliance Hannah E. Spencer, MSc, Amy.

Early Use of Inhaled Ribavirin Can Improve Outcomes in High Risk Hematopoietic Stem Cell Transplant and Leukemia Patients with RSV Infection Ron Mihelic,

Claudio Brunstein, MD, PhD, Keli Hippen, Todd E

A Single Nucleotide Polymorphism in SLC7A5 Is Associated with Gastrointestinal Toxicity after High-Dose Melphalan and Autologous Stem Cell Transplantation.

Trial in Progress: Gravitas-301, a Randomized, Double-Blind Phase 3 Study of Itacitinib or Placebo with Corticosteroids (CS) for the First-Line Treatment.

Distinctions Between Effective and Ineffective AML-Specific Autologous Peripheral Blood (PB) Cytotoxic T-Lymphocytes (CTLs) Rohtesh S. Mehta, MD MPH.

A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse Zeyad Kanaan, MD, William Tse, MD, FACP

Hematopoietic Cell Transplantation for Acute Leukemia and Advanced Myelodysplastic Syndrome in Fanconi Anemia Richard Mitchell, Todd Defor, John E. Wagner,

Annelies Billen, Jasmin B. L

Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L

Hemophagocytic Lymphohistiocytosis (HLH) after Hematopoietic Stem Cell Transplant (HSCT) or an Impostor: A Word of Caution! Anant Vatsayan, MD, Linda.

GVHD Prophylaxis with Post-Transplant High Dose Cyclophosphamide: Impact on Engraftment, Treatment-Related Mortality and Resource Utilization Nasheed.

Kamal Kant Singh Abbi, Junting Zheng, Sean M

Infection Prevention - Visitors and the Best of Intentions

Integrative Therapy Use as a Comfort Measure with BMT Patients

Outcome of Patients with Multiple Myeloma with t(4;14) after Autologous Hematopoietic Stem Cell Transplantation Koji Sasaki, MD, Rima Saliba, PhD, Gary.

Results of 10-Year Single Center Experience with Pharmacokinetics Directed Intravenous Busulfan, Cyclophosphamide and Etoposide Preparative Regimen in.

Single Center Experience with High Dose Melphalan and Two Day Washout in Patients with Multiple Myeloma on Hemodialysis Undergoing Autologous Stem Cell.

A Successful Approach to Decreasing Central Line Associated Blood Stream Infections Colleen Butcher, RN, BSN, OCN, Cindy Kramer, RN, BSN, OCN, Carrie.

Robust Donor Chimerism and Engraftment Following Familial Haploidentical (FHI) (CD34 Enriched and T-Cell Addback) Allogeneic Stem Cell Transplantation.

Incidence of Adrenal Insufficiency in Patients with Multiple Myeloma during High Dose Chemotherapy and Autologous Stem Cell Transplant Ahmad Hatem Mattour,

ASBMT and CBMTG Release Choosing Wisely BMT Recommendations

Mohammad Alhyari, M. D. , Aymen Bukannan, M. D. , Kimberly Brown, M. D

Guidance for Developing Phase II Cell Therapy Trial Proposals for Consideration by the Blood and Marrow Transplant Clinical Trials Network Edwin M. Horwitz,

Automated Production of Clinical-Grade CMV-Specific T Cells to Implement Immunotherapy at the Bedside Priti Tewari, MD, Pappanaicken R. Kumaresan, PhD,

September Mitchell, BSN, MHI, RN, CHTC, OCN, Sarah L

Redesigning Care to Lower Episode Costs in Bone Marrow Transplantation

Renee C. Gresh, DO, E. Anders Kolb, MD, Corinna L

Management of Cytokine Release Syndrome (CRS) in Patients Undergoing Chimeric Antigen Receptor Modified (CAR) T-Cell Therapy Following Autologous Stem.

Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond Stanley R. Riddell, Michael C. Jensen, Carl.

Blood and Marrow Transplant Handbook

Influence of Body Weight on Melphalan Dosing in Autologous Stem Cell Transplantation Kendall Shultes, Christopher Arp, Keith Stockerl-Goldstein, Kathryn.

Evaluation of a Data-Derived Algorithm for Preemptive Use of Plerixafor for Stem Cell Harvest in Patients Eligible for Autologous Stem Cell Transplant.

Higher Total Nucleated Cell Dose, but Not CD3+, 4+, 8+, or 34+ Cell Dose, Is Associated with Better Overall and Progression-Free Survival after Allogeneic.

Mammen Chandy Biology of Blood and Marrow Transplantation

Heather A. Himburg, PhD, Liman Zhao, Jenny Kan, John P. Chute, M.D.

Identification of CD137+ IFN-g- CD4+ Alloreactive T Cells Post Myeloablative Double Cord Blood Transplant: A Synergistic Role in the Graft Verus Graft.

Treatment versus Transplant for Challenging Hematologic Disorders

Lawyers Partnering with the BMT Team: Impact on Patient Perception of Legal Concerns and Well-Being Leslie Parran, RN, MS, AOCN, NE-BC, BMTCN, Kathryn.

Monocyte Recovery at Day 100 Is Associated with Improved Survival in Multiple Myeloma Patients Who Undergo Allogeneic Hematopoietic Cell Transplantation

In Memoriam: E. Donnall Thomas

The Incidence and Outcomes of Oral Mucositis Among Allogeneic Stem Cell Transplantation Patients: A Systematic Review and Meta-Analysis Hafsa Myedah.

Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma Luciano J. Costa, Jia-Xing Huang, Parameswaran.

Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective.

Presentation transcript:

A Prospective, Randomized Clinical Trial of Cryotherapy Vs A Prospective, Randomized Clinical Trial of Cryotherapy Vs. Supersaturated Calcium Phosphate Rinses Vs. Saline Rinses for the Prevention of Oral Mucositis in Patients with Multiple Myeloma (MM) Receiving High-Dose Melphalan (HDM) and Autotransplantation Juan J. Toro, MD, MSCI, Deanna Schneider, BSN, Rosalinda Alonzo, RN, Abida Hasan, MS, Shuko Lee, MS, Francisca Gushiken, MD, David J. Haile, MD, Cesar O. Freytes, MD Biology of Blood and Marrow Transplantation Volume 20, Issue 2, Pages S204-S205 (February 2014) DOI: 10.1016/j.bbmt.2013.12.340 Copyright © 2014 Terms and Conditions

Biology of Blood and Marrow Transplantation 2014 20, S204-S205DOI: (10 Biology of Blood and Marrow Transplantation 2014 20, S204-S205DOI: (10.1016/j.bbmt.2013.12.340) Copyright © 2014 Terms and Conditions